IDÀúÀå 
ùȭ¸éÀ¸·Î
°øÁö»çÇ×
°Ô½ÃÆÇ
ÄûÁîÄûÁî
ÁÖÀÓ±³¼ö Àλ縻
µ¿¹®È¸Àå Àλ縻
±³½Ç¿ª»ç
¿ª´ë ÁÖÀÓ±³¼ö
¿ª´ë µ¿¹®È¸Àå
±³½Ç¿ø ¼Ò°³
Àü°øÀÇ ¼Ò°³
ÀÚÁÖ ¿¬¶ôÇսôÙ
°ø½ÄÇà»ç
¿ì¸®´Â Çϳª
Ãß¾ïÀÇ ¾Ù¹ü
News Letter
¿¬º¸
¼ö¿ä Conference
¿©Àǵµ¼º¸ð
°­³²¼º¸ð
ÀÇÁ¤ºÎ¼º¸ð
¼ººó¼¾Æ®
¼º¸ðÀÚ¾Ö
¼º°¡
¼º¹Ù¿À·Î
´ëÀü¼º¸ð
°¡Å縯½ÉÆ÷Áö¿ò
µ¿¹®Çмú´ëȸ
º¸¹°Ã¢°í
µðīŬ·´
Á¤º¸¼öÁ¤
ÀÔÅð¿ø¼ö¼ú °ü¸®

 
ÀÛ¼ºÀÚ ºñ´¢±â°úÇб³½Ç µî·ÏÀÏ 2010-05-25 14:32:21
Á¶È¸ 675 ´Ù¿î 0
Á¦¸ñ   5¿ù26ÀÏ ¼ö¿äÃʵ¶È¸ °øÁö
÷ºÎÆÄÀÏ    
³»¿ë
4¿ù 21ÀÏ ¼ö¿äÃʵ¶È¸ °øÁö

PDE5 inhibitor and BPH/LUTS
ÁÂÀå: ±èÇö¿ì ±³¼ö

¹ßÇ¥ :
R4: À̵¿¼· Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol. 2010;20(1):49-54
     
R3: ÃÖÁøºÀ Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int. 2009 ;104(4):511-7



ÀϽà : 2010³â 5¿ù 26ÀÏ ¿ÀÈÄ 5½Ã 30ºÐ
Àå¼Ò : ¼º¸ðº´¿ø 4Ãþ ´ë°­´ç

ÄÁÆÛ·±½ºÈÄ µ¿¹®ÃÑȸ°¡ ÀÖ½À´Ï´Ù.

ÀÌÀü±Û   È²ÅÂ°ï ±³¼ö´Ô ȸ°©¿¬
ÀÌÈÄ±Û   5¿ù 12ÀÏ ¼ö¿äÃʵ¶È¸ °øÁö

 
¸®Çôޱâ